What is William Blair’s Estimate for MaxCyte Q1 Earnings?

MaxCyte, Inc. (NASDAQ:MXCT) – Equities research analysts at William Blair issued their Q1 2025 earnings estimates for shares of MaxCyte in a report released on Wednesday, March 12th. William Blair analyst M. Larew forecasts that the company will post earnings of ($0.10) per share for the quarter. The consensus estimate for MaxCyte’s current full-year earnings is ($0.42) per share. William Blair also issued estimates for MaxCyte’s Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.34) EPS.

A number of other equities research analysts have also recently issued reports on MXCT. Stifel Nicolaus dropped their target price on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday. BTIG Research set a $6.00 target price on shares of MaxCyte and gave the company a “buy” rating in a report on Wednesday.

MaxCyte Stock Performance

Shares of MXCT stock opened at $3.29 on Friday. The firm’s 50-day moving average is $4.17 and its 200-day moving average is $3.97. The stock has a market cap of $348.61 million, a price-to-earnings ratio of -9.68 and a beta of 1.35. MaxCyte has a 52-week low of $2.76 and a 52-week high of $5.26.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. grew its stake in MaxCyte by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company’s stock valued at $93,000 after buying an additional 2,154 shares during the last quarter. Rhumbline Advisers grew its stake in MaxCyte by 1.6% in the 4th quarter. Rhumbline Advisers now owns 153,655 shares of the company’s stock valued at $639,000 after buying an additional 2,402 shares during the last quarter. Valmark Advisers Inc. grew its stake in MaxCyte by 2.2% in the 4th quarter. Valmark Advisers Inc. now owns 115,654 shares of the company’s stock valued at $481,000 after buying an additional 2,478 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in MaxCyte by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,929 shares of the company’s stock valued at $249,000 after buying an additional 2,584 shares during the last quarter. Finally, Invesco Ltd. grew its stake in MaxCyte by 8.5% in the 4th quarter. Invesco Ltd. now owns 49,096 shares of the company’s stock valued at $204,000 after buying an additional 3,848 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.